Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,503
Total Claims
$2.3M
Drug Cost
656
Beneficiaries
$3,535
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+132%
Cost per patient vs peers
$3,535 vs $1,524 avg
+61%
Brand preference vs peers
21.9% vs 13.7% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
0.2%
Opioid Rate
23
Opioid Claims
$175
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,304 claims · $2.1M
Generic: 8,199 claims · $220K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Evinacumab-Dgnb | 13 | $539K |
| Rivaroxaban | 512 | $359K |
| Apixaban | 426 | $322K |
| Sacubitril/Valsartan | 259 | $218K |
| Icosapent Ethyl | 146 | $75K |
| Vorapaxar Sulfate | 123 | $73K |
| Ticagrelor | 122 | $70K |
| Semaglutide | 51 | $63K |
| Ranolazine | 528 | $55K |
| Empagliflozin | 54 | $48K |
| Finerenone | 39 | $44K |
| Linaclotide | 55 | $42K |
| Dapagliflozin Propanediol | 51 | $37K |
| Alirocumab | 42 | $30K |
| Vericiguat | 41 | $28K |
Prescribing Profile
Patient Profile
70
Avg Age
62%
Female
2.08
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About